ReviewInternational journal of nanomedicine2025
Metal-Based Nanomedicines for Inducing Programmed Cell Death to Enhance the Efficacy of Cancer Immunotherapy.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Metal Ions: Engineering Biomaterials for Multimodal Disease Treatment.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal ions exert indispensable functions in various physiological processes, and metal ion homeostasis is needed in cells. Intracellular metal ion homeostasis is regulated by their efflux and influx across the cell membrane. Dysregulation of intracellular metallic ions can trigger programmed cell death (PCD). In recent years, metallic ions as potent immunomodulators and enhancers for cancer immunotherapy through modulating the immunosuppressive tumor microenvironment and triggering an immunostimulatory response have been extensively explored. The review focuses on the mechanism of PCD and immunomodulatory effects for various metal ions including iron, copper, calcium, zinc, and manganese, and provides a systematic overview of nanoparticles for delivering metallic ions or constructed of metals to realize PCD and enhance cancer immunotherapy. Finally, the prospect and challenges of clinic translation of metal-based nano-drug delivery systems in cancer therapy are outlined, and especially restriction of large-scale manufacturing and safety concern for clinic translation are further discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.